BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: Nivolumab
Other: Best Supportive Care
Drug: Erlotinib
Drug: Crizotinib
Drug: Pemetrexed
Drug: nab-Paclitaxel
Drug: Paclitaxel
Drug: Docetaxel
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2015-10-12

Last Posted Date: 2021-05-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 341

Registration Number: NCT02574078

Locations: 🇺🇸
Cancer Care Center, Bismarck, North Dakota, United States
🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸
Texas Oncology Cancer Center - Sugar Land, Sugar Land, Texas, United States

and more 119 locations

A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C

Phase 1

Completed

Conditions: Renal Transplantation

Interventions: Biological: Process E Belatacept
Biological: Process C Belatacept

First Posted Date: 2015-09-30

Last Posted Date: 2019-04-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 491

Registration Number: NCT02564497

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: Methotrexate
Drug: Adalimumab

First Posted Date: 2015-09-23

Last Posted Date: 2020-09-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 80

Registration Number: NCT02557100

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇲🇽
Clinica de Investigacion en Reumatologia y Obesidad S.C., Guadalajara, Jalisco, Mexico
🇲🇽
Clinica Integral en Osteoporosis y Artritis CLINOSAR Mexico S.A. de C.V., Mexico D.F., Mexico

and more 24 locations

A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)

Phase 2

Withdrawn

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Sofosbuvir

First Posted Date: 2015-09-22

Last Posted Date: 2016-01-20

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02556086

Locations: 🇫🇷
Local Institution, Pessac, France

A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3

Phase 2

Withdrawn

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Sofosbuvir
Drug: Ribavirin

First Posted Date: 2015-09-16

Last Posted Date: 2016-01-15

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02551861

Locations: 🇫🇷
Local Institution, Vandoeuvre Les Nancy, France

Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMS

Completed

Conditions: Venous Thromboembolism

First Posted Date: 2015-09-11

Last Posted Date: 2017-10-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 29

Registration Number: NCT02546817

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

Completed

Conditions: Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2015-09-11

Last Posted Date: 2017-07-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 101

Registration Number: NCT02546791

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Phase 3

Completed

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Drug: Dacarbazine

First Posted Date: 2015-09-09

Last Posted Date: 2020-05-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 182

Registration Number: NCT02545075

Locations: 🇨🇳
Local Institution, Shanghai, China

An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Biological: Nivolumab
Other: Placebo
Biological: Ipilimumab

First Posted Date: 2015-09-02

Last Posted Date: 2023-01-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 907

Registration Number: NCT02538666

Locations: 🇲🇽
Local Institution - 0020, Leon de los Aldama, Guanajuato, Mexico
🇧🇷
Local Institution - 0063, Ijui, RIO Grande DO SUL, Brazil
🇨🇳
Local Institution - 0244, Wuhang, Hubei, China

and more 173 locations

A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body

Phase 1

Completed

Conditions: Liver Fibrosis/NASH

Interventions: Drug: BMS-986171
Other: Placebo

First Posted Date: 2015-09-02

Last Posted Date: 2017-05-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 275

Registration Number: NCT02538874

Locations: 🇺🇸
Profil Institute For Clinical Research, Inc., Chula Vista, California, United States
🇺🇸
Wcct Global, Llc, Cypress, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy